You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 795 A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Article metrics

Article menu

Download PDFPDF

Late-breaking abstracts
Clinical trials completed
795 A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020566075
Dec 202076010
Jan 202168011
Feb 202154010
Mar 202174017
Apr 202184016
May 202115017
Jun 20210013
Jul 20210032
Aug 20210019
Sep 20210013
Oct 202140032
Nov 202130019
Dec 20212205
Jan 20223804
Feb 20223205
Mar 20222202
Apr 20225003
May 20227003
Jun 20223203
Jul 20223601
Aug 20229208
Sep 20223602
Oct 20223400
Nov 20222401
Dec 2022802
Jan 20233002
Feb 20233003
Mar 20231800
Apr 20233002
May 20232604
Jun 20231400
Jul 20232008
Aug 20231002
Sep 20231200
Oct 20231805
Nov 20232401
Dec 20232200
Jan 20242400
Feb 20241001
Mar 20244001
Apr 20241802
May 20242601
Jun 20243902
Jul 20241804
Aug 20242901
Sep 20243603
Oct 20242007
Nov 2024806
Dec 20241808
Jan 20252406
Feb 20251006
Mar 2025005
Apr 2025005
May 2025008
Jun 2025204
Total20790420